Description

Tulizid (ceftazidime) powder for solution for injections 1 g. vial №1

Ingredients:

Each vial contains ceftazidime (as ceftazidime pentahydrate) 1 g.

Dosage:

The dosage and duration of therapy should be determined by a healthcare provider. Tulizid is usually administered by intravenous infusion over 30 minutes. The usual adult dose is 1 to 6 g daily in divided doses.

Indications:

Tulizid is indicated for the treatment of infections caused by susceptible strains of microorganisms. It is commonly used in the treatment of lower respiratory tract infections, urinary tract infections, skin and skin structure infections, and intra-abdominal infections.

Contraindications:

Do not use Tulizid if there is a known hypersensitivity to ceftazidime or other cephalosporins. Caution should be exercised in patients with a history of penicillin allergy.

Directions:

Tulizid should be reconstituted with the appropriate diluent as directed before administration. It is important to follow aseptic techniques during reconstitution.

Scientific Evidence:

Ceftazidime, the active ingredient in Tulizid, is a third-generation cephalosporin antibiotic with a broad spectrum of activity against many Gram-negative bacteria. Studies have shown its efficacy in various infections, including nosocomial pneumonia and complicated urinary tract infections.

Additional Information:

It is essential to monitor renal function in patients receiving Tulizid due to the risk of nephrotoxicity. The drug may also cause gastrointestinal disturbances and allergic reactions. Consult a healthcare professional for personalized recommendations.

Research has indicated that ceftazidime demonstrates good stability and efficacy in the treatment of Pseudomonas aeruginosa infections, making it a valuable option in clinical practice.